[Ip-health] DNDi Welcomes New MPP Licensing Agreement and Joins PEPFAR, Global Fund, PHTI Commitment to Reduce HIV Treatment Gap for HIV-Positive Children

Rachel Cohen rachel.cohen72 at gmail.com
Mon Dec 1 11:37:38 PST 2014


World AIDS Day 2014: DNDi Welcomes New Medicines Patent Pool Licensing
Agreement and Joins PEPFAR, Global Fund, PHTI Commitment to Reduce HIV
Treatment Gap for HIV-Positive Children  

[Geneva, Switzerland, and New York, USA, 1 December 2014] The Drugs for
Neglected Diseases initiative (DNDi) welcomes the
e-for-hiv-paediatric-formulations-of-lopinavir-and-ritonavir/> Medicines
Patent Pool announcement this World AIDS Day that it has negotiated an
agreement with AbbVie, which is placing two key paediatric HIV medicines,
lopinavir andritonavir, into the Pool. The agreement means that where 99% of
children with HIV live, there will be no intellectual property barriers to
the development or delivery of much-needed improved paediatric
antiretroviral (ARV) formulations, including a key lopinavir/ritonavir-based
treatment that DNDi and its partner Cipla are developing for infants and
young children. Importantly, the MPP-AbbVie agreement includes South Africa,
which has the highest burden of paediatric HIV in the world.


‘With intellectual property barriers formally lifted from lopinavir and
ritonavir, the two key components of the World Health Organization’s
recommended first-line antiretroviral regimen for paediatrics, more children
with HIV will be able to access improved formulations more rapidly’, said Dr
Marc Lallemant, Head of the Paediatric HIV Programme at DNDi. ‘This is
particularly the case for South Africa, where children are given the current
liquid formulation that has an unbearable taste, is full of alcohol, and is
difficult for caregivers to administer.’

The ‘Global Pediatric ARV Commitment-to-Action’ was also announced today, by
the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the Global
Fund to Fight AIDS, Tuberculosis and Malaria, and the Paediatric HIV
Treatment Initiative (PHTI) - a collaboration between UNITAID, the Clinton
Health Access Initiative (CHAI), MPP, and DNDi. These key partners have
joined forces to accelerate development of priority paediatric ARVs within
the next three years, through incentivizing drug manufacturers to develop
and supply ARVs, and through facilitating regulatory approval, adoption, and
rapid uptake in hard-hit countries as soon as the drugs are available.

‘Paediatric HIV has long been comparable to a neglected disease, with a lack
of child-friendly formulations and poor diagnostic options contributing to a
high death rate in HIV-positive children’, said Dr Bernard Pécoul, Executive
Director, DNDi. ‘Today’s agreements are another promising step towards
reducing the unacceptable HIV treatment gap between kids and adults. Let us
hope these commitments will translate into immediate action.’

DNDi’s work in Paediatric HIV/AIDS
DNDi is currently working with Cipla Ltd and other partners to develop an
improved first-line therapy for infants and toddlers living with HIV. The
project aims to develop two solid 4-in-1 fixed-dose combinations:
lopinavir/ritonavir/zidovune/lamivudine (LPV/r/AZT/3TC) and
lopinavir/ritonavir/abacavir/ lamivudine (LPV/r/ABC/3TC). DNDi and Cipla
will also develop a stand-alone solid granule version of ritonavir to be
added to paediatric treatment when children are co-infected with
tuberculosis (TB), as additional ‘boosts’ of ritonavir, to do away with the
negative interaction between the TB medicine rifampicin and ARVs.

This project is made possible with support from UNITAID, the French
Development Agency (AFD), Médecins Sans Frontières (MSF), and the UBS
Optimus Foundation. Read DNDi's paediatric HIV overview, "Accelerating the
Development and Delivery of Antiretroviral Treatment for Children with
ember_2013.pdf> pdf]

About Paediatric HIV/AIDS
An estimated 3.3 million children under the age of 15 years are living with
HIV/AIDS, 3.1 million of whom (94%) live in sub-Saharan Africa. Each day,
some 700 children are newly infected with HIV and 500 die from AIDS-related
complications. Only one-third of HIV-positive children who need treatment
are receiving it. Without treatment, one-third of children born with HIV
will die before their first birthday, 50% will die before they turn two, and
80% will die before they are five years old.

About the Drugs for Neglected Diseases initiative (DNDi)
DNDi is a not-for-profit research and development organization working to
deliver new treatments for neglected diseases, in particular human African
trypanosomiasis, Chagas disease, leishmaniasis, filaria, and paediatric HIV.
DNDi was established in 2003 by Médecins Sans Frontières/Doctors Without
Borders (MSF), Oswaldo Cruz Foundation of Brazil, Indian Council for Medical
Research, Kenya Medical Research Institute, Ministry of Health of Malaysia,
and Institut Pasteur of France. The WHO Special Programme for Research and
Training in Tropical Diseases (WHO-TDR) serves as a permanent observer.
Since 2003, DNDi has delivered six treatments for neglected patients: two
fixed-dose drug combinations for malaria (ASAQ and ASMQ);
nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping
sickness; sodium stibogluconate and paromomycin (SSG&PM) combination therapy
for visceral leishmaniasis in Africa; a set of combination therapies for
visceral leishmaniasis in Asia; and a paediatric formulation of benznidazole
for Chagas disease.
 <http://www.dndi.org/> www.dndi.org

Media contacts:
DNDi, Violaine Dallenbach (Europe) +41 79 424 14 74;
<mailto:vdallenbach at dndi.org> vdallenbach at dndi.org
DNDi, Ilan Moss (USA) +1-646-266-5216;  <mailto:imoss at dndi.org>
imoss at dndi.org




More information about the Ip-health mailing list